Cargando…

Effects of Selective Serotonin Reuptake Inhibitor Treatment on Ovarian Reserves in Patients with Depression

Background and Objectives: The goal of this study was to investigate the effect of selective serotonin reuptake inhibitor treatment on the ovarian reserves of women of reproductive age with major depressive disorder. Materials and Methods: The current study is a prospective controlled trial includin...

Descripción completa

Detalles Bibliográficos
Autores principales: Gök, Soner, Gök, Berfin Can, Alataş, Erkan, Senol, Hande, Topak, Osman Zülkif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058318/
https://www.ncbi.nlm.nih.gov/pubmed/36984518
http://dx.doi.org/10.3390/medicina59030517
_version_ 1785016598528000000
author Gök, Soner
Gök, Berfin Can
Alataş, Erkan
Senol, Hande
Topak, Osman Zülkif
author_facet Gök, Soner
Gök, Berfin Can
Alataş, Erkan
Senol, Hande
Topak, Osman Zülkif
author_sort Gök, Soner
collection PubMed
description Background and Objectives: The goal of this study was to investigate the effect of selective serotonin reuptake inhibitor treatment on the ovarian reserves of women of reproductive age with major depressive disorder. Materials and Methods: The current study is a prospective controlled trial including 48 women with major depressive disorder and 48 age-matched healthy controls. Ovarian reserve tests are performed prior to treatment and after six cycles of selective serotonin reuptake inhibitor treatment in the major depressive disorder group. Serum follicle-stimulating hormone, luteinizing hormone, estradiol, and anti-Müllerian hormone levels were evaluated from blood samples, and endometrial thickness, total antral follicle count, and volume of both ovaries were assessed using transvaginal ultrasonography. Results: When the first measurements were compared, menstrual duration and menstrual bleeding increased (p = 0.007 and 0.005, respectively) and luteinizing hormone decreased (p = 0.045) in the major depressive disorder group, while follicle-stimulating hormone, estradiol, anti-Müllerian hormone, endometrial thickness, total antral follicle count, and mean ovarian volume did not differ significantly between groups (p > 0.05). When the major depressive disorder group’s first and final measurements were compared, follicle-stimulating hormone, estradiol, and endometrial thickness increased (p = 0.05, 0.0001, and 0.005, respectively), luteinizing hormone remained constant (p = 0.541), and anti-Müllerian hormone and total antral follicle count decreased (p = 0.024 and 0.042, respectively). Conclusions: In this study, we observed that the ovarian reserve test results of patients diagnosed with major depression for the first time after 6 months of SSRI treatment were significantly different from the results of the pretreatment and control groups.
format Online
Article
Text
id pubmed-10058318
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100583182023-03-30 Effects of Selective Serotonin Reuptake Inhibitor Treatment on Ovarian Reserves in Patients with Depression Gök, Soner Gök, Berfin Can Alataş, Erkan Senol, Hande Topak, Osman Zülkif Medicina (Kaunas) Article Background and Objectives: The goal of this study was to investigate the effect of selective serotonin reuptake inhibitor treatment on the ovarian reserves of women of reproductive age with major depressive disorder. Materials and Methods: The current study is a prospective controlled trial including 48 women with major depressive disorder and 48 age-matched healthy controls. Ovarian reserve tests are performed prior to treatment and after six cycles of selective serotonin reuptake inhibitor treatment in the major depressive disorder group. Serum follicle-stimulating hormone, luteinizing hormone, estradiol, and anti-Müllerian hormone levels were evaluated from blood samples, and endometrial thickness, total antral follicle count, and volume of both ovaries were assessed using transvaginal ultrasonography. Results: When the first measurements were compared, menstrual duration and menstrual bleeding increased (p = 0.007 and 0.005, respectively) and luteinizing hormone decreased (p = 0.045) in the major depressive disorder group, while follicle-stimulating hormone, estradiol, anti-Müllerian hormone, endometrial thickness, total antral follicle count, and mean ovarian volume did not differ significantly between groups (p > 0.05). When the major depressive disorder group’s first and final measurements were compared, follicle-stimulating hormone, estradiol, and endometrial thickness increased (p = 0.05, 0.0001, and 0.005, respectively), luteinizing hormone remained constant (p = 0.541), and anti-Müllerian hormone and total antral follicle count decreased (p = 0.024 and 0.042, respectively). Conclusions: In this study, we observed that the ovarian reserve test results of patients diagnosed with major depression for the first time after 6 months of SSRI treatment were significantly different from the results of the pretreatment and control groups. MDPI 2023-03-07 /pmc/articles/PMC10058318/ /pubmed/36984518 http://dx.doi.org/10.3390/medicina59030517 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gök, Soner
Gök, Berfin Can
Alataş, Erkan
Senol, Hande
Topak, Osman Zülkif
Effects of Selective Serotonin Reuptake Inhibitor Treatment on Ovarian Reserves in Patients with Depression
title Effects of Selective Serotonin Reuptake Inhibitor Treatment on Ovarian Reserves in Patients with Depression
title_full Effects of Selective Serotonin Reuptake Inhibitor Treatment on Ovarian Reserves in Patients with Depression
title_fullStr Effects of Selective Serotonin Reuptake Inhibitor Treatment on Ovarian Reserves in Patients with Depression
title_full_unstemmed Effects of Selective Serotonin Reuptake Inhibitor Treatment on Ovarian Reserves in Patients with Depression
title_short Effects of Selective Serotonin Reuptake Inhibitor Treatment on Ovarian Reserves in Patients with Depression
title_sort effects of selective serotonin reuptake inhibitor treatment on ovarian reserves in patients with depression
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058318/
https://www.ncbi.nlm.nih.gov/pubmed/36984518
http://dx.doi.org/10.3390/medicina59030517
work_keys_str_mv AT goksoner effectsofselectiveserotoninreuptakeinhibitortreatmentonovarianreservesinpatientswithdepression
AT gokberfincan effectsofselectiveserotoninreuptakeinhibitortreatmentonovarianreservesinpatientswithdepression
AT alataserkan effectsofselectiveserotoninreuptakeinhibitortreatmentonovarianreservesinpatientswithdepression
AT senolhande effectsofselectiveserotoninreuptakeinhibitortreatmentonovarianreservesinpatientswithdepression
AT topakosmanzulkif effectsofselectiveserotoninreuptakeinhibitortreatmentonovarianreservesinpatientswithdepression